*Refresh the page if the below document does not appear.
Global healthcare major Viatris, MedAccess, and TB Alliance have announced a collaboration to reduce the price of its multidrug-resistant tuberculosis treatment drug ‘Pretomanid’ , by 34%. Globally, only twothirds of the multi-drug resistant TB patients are able to be cured.
Uday Bhaskar, the director General of the Pharmaceuticals Export Promotion Council of India (Pharmexcil) mentioned that the RussiaUkraine war did not have any significant impact on the Pharma business and that the Indian pharmaceutical industry should focus on complex generics formulations, biopharmaceuticals, and more.
Prejex Inc. has signed a pact with Polybond, headed by Adit Rathi of Rathi Group, to produce needleless injections. This deal has enabled the shifting of German manufacturing capabilities from Berlin in Germany to Pune in India.
Glenmark Pharmaceuticals announced that they have received final approval from US FDA for Nicardipine Hydrochloride Capsules, 20 mg, and 30 mg. According to the reports, it is the generic version of Cardene Capsules, 20 mg, and 30 mg, by Chiesi USA, Inc.
On Monday, AstraZeneca announced that its drug Imfinzi failed to show positive results for improving overall survival in comparison with platinum-based chemotherapy as a monotherapy treatment of patients with latestage non-small cell lung cancer.
The reduced number of COVID-19 cases appears to have put the city of Hyderabad at too much ease, as the district-wise data showed that only 20% of the city’s eligible population opted for the precaution dose, making it remain at the bottom of the list.
Atara Biotherapeutics company announced
that its allogeneic Epstein-Barr virus-positive
(EBV) T-cell therapy tabelecleucel has received
the world-first approval in Europe. Atara’s drug
collects T-cells from healthy donors, unlike
other autologous cell therapies in the market.
If you don’t already have an account click the button below to create your account.Create New Account
Please update your profile to keep using the website